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The discovery of Glucagon-like peptide 1 (GLP-1) has
prompted an important series of advances in our under-
standing of how the gut and the pancreas interact to
regulate the physiology of food ingestion. GLP-1 par-
tially accounts for the incretin effect, whereby orally
ingested carbohydrates produce an augmented pancreatic
islet hormone response compared to the same amount of
carbohydrate delivered intravenously; more generally,
GLP-1 and related gut peptides are now understood to
integrate food absorption and pancreatic islet function.
These discoveries have led to important advances in the
clinical care of diabetes, with two classes of drugs (and
an expanding set of choices within each class) that
work through the GLP-1 system now available for the
treatment of diabetes.
GLP-1 is an evolutionarily ancient hormone, with
analogs or paralogs present in vertebrate species and
fish. However, the functions of GLP-1 appear to differ
among species, and even in higher vertebrates there
appear to be a variety of physiologic functions for
GLP-1. The existence of the classical GLP-1 receptor
in tissues outside the entero-endocrine axis has been
recognized, including the heart, the kidney and the
brain. The physiologic roles of GLP-1 in these and
other locations have been the subject of an expanding
interest in the various extra pancreatic functions of
GLP-1.
The current issue of Reviews in Endocrine and Met-
abolic Disorders includes state-of-the-art reviews of the
major recognized extra pancreatic functions of GLP-1.
These include manuscripts exploring the contributions of
GLP-1 to the regulation of appetite and weight, and an
exploration of the role that GLP-1 may play in produc-
ing or maintaining the weight loss associated with
weight loss surgery. These phenomena are not just of
academic interest regarding the physiology of energy
balance, but rather provide us with opportunities to
better understand the systems at work and highlight
the potential to use GLP-1 based therapies to modify
weight and energy balance. Interestingly, GLP-1 may be
one of many host axes that are affected by, and in turn
affect, the gut microbiota and the increasingly recog-
nized symbiotic phenomena that contribute to human
gut physiology and pathophysiology. Papers reviewing
the effects of GLP-1 in the kidney and the heart dem-
onstrate that GLP-1 is an important contributor to the
regulation of whole-body sodium balance, and contrib-
utes to the regulation of hemodynamics. Perhaps the
most exciting therapeutic advances may come from the
application of GLP-1 based treatments for the treatment
of myocardial or cerebral ischemia, and we present
papers explaining the genesis of this idea and reviewing
the current evidence.
Safe and effective GLP-1 based treatments have been
developed and are approved for the treatment of human
diabetes (and likely also for weight management in the
near future). These agents are primed for deployment in
other realms of disease, although the effective dosing
and achievable treatment benefits remain to be
established. In the near term these agents may come to
be used for stroke and myocardial infarction, but possi-
ble uses in other conditions abound and the barriers to
testing are comparatively low. Therefore it is possible
that in the future GLP-1 based treatments may be as
widely used for extra pancreatic benefits as for treat-
ment of diabetes. Welcome to the future!
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